Segment Reporting (Details)		12 Months Ended
		Dec. 31, 2024 USD ($) Segment	Dec. 31, 2023 USD ($)
Segment Information [Abstract]
Number of operating segments | Segment		1
Number of reportable segments | Segment		1
Sales		$ 1,629,108	$ 1,071,970
Cost of sales (excluding depreciation expense)		544,903	380,069
Total research and development expense		8,216,543	7,208,701
Sales and marketing expense		4,030,150	650,126
General and administrative expense		6,325,999	6,858,008
Depreciation and amortization expense		297,318	483,481
Total operating expenses		18,870,010	15,200,316
Total other (expense) income		(1,021,221)	265,629
Loss before income taxes		(18,807,026)	(14,242,786)
Income tax expense		9,602	4,338
Net loss		(18,816,628)	(14,247,124)
Business Segment [Member]
Segment Information [Abstract]
Sales		1,629,108	1,071,970
Cost of sales (excluding depreciation expense)		544,903	380,069
Research and development expense		2,217,610	2,051,902
Other research and development expense	[1]	5,998,933	5,156,799
Total research and development expense		8,216,543	7,208,701
Sales and marketing expense		4,030,150	650,126
General and administrative expense		6,325,999	6,858,008
Depreciation and amortization expense		297,318	483,481
Total operating expenses		18,870,010	15,200,316
Total other (expense) income		(1,021,221)	265,629
Loss before income taxes		(18,807,026)	(14,242,786)
Income tax expense		9,602	4,338
Net loss		$ (18,816,628)	$ (14,247,124)

[1] Other research and development expenses include clinical affairs, regulatory, manufacturing and quality assurance expenses.